Get the Stockscreener App
5.19
0.00%
0.00
After Hours:
5.19
Cadrenal Therapeutics Inc stock is traded at $5.19, with a volume of 72,312.
It is up +0.00% in the last 24 hours and down -5.64% over the past month.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
See More
Previous Close:
$5.19
Open:
$5.24
24h Volume:
72,312
Relative Volume:
1.24
Market Cap:
$15.98M
Revenue:
-
Net Income/Loss:
$-11.89M
P/E Ratio:
-0.9216
EPS:
-5.6317
Net Cash Flow:
$-10.96M
1W Performance:
+4.43%
1M Performance:
-5.64%
6M Performance:
-44.67%
1Y Performance:
-64.81%
1-Day Range:
$5.05
$5.59
1-Week Range:
$4.8311
$5.8855
52-Week Range:
$4.21
$15.99
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
5.19 | 15.98M | 0 | -11.89M | -10.96M | -5.6317 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
CVKD Q1 2026 Earnings: Narrower Loss Surprises; Clinical Progress MaintainedCrowd Risk Alerts - Newser
CVKD Q1 2026 Earnings: Narrowing Losses and Steady Progress in Clinical PipelineMarket Hype Signals - Newser
CVKD Stock Price, Quote & Chart | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
CVKD Technical Analysis | Trend, Signals & Chart Patterns | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Cadrenal Therapeutics to present at Lytham Partners Spring 2026 Investor Conference on May 28 - Pluang
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - marketscreener.com
(CVKD) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Number of shareholders of Cadrenal Therapeutics, Inc. – NASDAQ:CVKD - TradingView
symbol__ Stock Quote Price and Forecast - CNN
CVKD stock retail sentiment peaks after FDA clears phase 3 path for blood clot drug - MSN
TradingKey - TradingKey
[144] Cadrenal Therapeutics, Inc. SEC Filing - Stock Titan
CVKD: Designing Phase 3 Trial for CAD-1005 in HIT - Yahoo Finance
Responsive Playbooks and the CVKD Inflection - Stock Traders Daily
Cadrenal receives FDA guidance for phase 3 HIT trial By Investing.com - Investing.com South Africa
Cadrenal receives FDA guidance for phase 3 HIT trial - Investing.com
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA - The Manila Times
Cadrenal Therapeutics, Inc. released its financial results for the first quarter of 2026 and provided updates on the Phase III clinical trial plans for its core drug, CAD-1005. - Bitget
Cadrenal Therapeutics, Inc. 1Q 2026: Net income $(2.50M), EPS $(1.04) — 10-Q Summary - TradingView
Cadrenal (NASDAQ: CVKD) cuts Q1 loss and readies CAD-1005 Phase 3 trial - Stock Titan
Cadrenal targets 120-patient global Phase 3 trial for HIT drug - Stock Titan
Cash strain and Nasdaq equity risk for Cadrenal (NASDAQ: CVKD) - Stock Titan
CVKD Q1'26 Earnings: EPS estimate is (1.51) USD - TradingView
Cadrenal Therapeutics Inc expected to post a loss of $1.62 a shareEarnings Preview - TradingView
CVKD Stock Retail Sentiment Peaks After FDA Clears Phase 3 Path For Blood Clot Drug - Stocktwits
Noble Financial Reaffirms Their Buy Rating on Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Cartesian Therapeutics (RNAC), Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA - TipRanks
Cadrenal Therapeutics Receives FDA Guidance for Pivotal Phase 3 Trial of CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) - Minichart
Cadrenal Advances CAD-1005 Into FDA-Guided Phase 3 Trial - TipRanks
Cadrenal receives FDA guidance to advance CAD-1005 to phase 3 trial - Investing.com
Cadrenal Therapeutics advances CAD-1005 to pivotal Phase 3 after FDA End-of-Phase 2 meeting - TradingView
Cadrenal receives FDA guidance to advance CAD-1005 to phase 3 trial By Investing.com - Investing.com South Africa
FDA backs CAD-1005 Phase 3 HIT trial path at Cadrenal (NASDAQ: CVKD) - Stock Titan
Cadrenal Therapeutics Announces End-Of-Phase 2 Meeting with the Fda and Pivotal Phase 3 Registration Path for Cad-1005 in Heparin-Induced Thrombocytopenia - marketscreener.com
[EFFECT] Cadrenal Therapeutics, Inc. SEC Filing - Stock Titan
Cadrenal Therapeutics (CVKD) registers 1.18M shares for resale under S-3 - Stock Titan
Understanding the Setup: (CVKD) and Scalable Risk - Stock Traders Daily
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cadrenal Therapeutics Inc Stock (CVKD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Szot Matthew K | Chief Financial Officer |
Dec 29 '25 |
Sale |
6.97 |
9,933 |
69,233 |
0 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):